JPM2024 Recap & Global Biotech Outlook | 药时代直播间

SAPA-GP Webinar

SAPA-GP Webinar welcome you to attend:

BioVerse: Where Science Sparks Business【Episode 005】

JPM2024 Recap & Global Biotech Outlook | 药时代直播间

Introduction

Biotech finished 2023 in black, after a turbulent 2023. Going into 2024, people expect tailwinds such as the US interest rate decrease, strong biopharma cash position, and continuous influx of expected major catalysts, as well as the headwinds of incoming presidential election, implementation of IRA and more.

Join our group of biotech veterans who have decades of experiences in entrepreneurship, BD, private investment, public investment, and policies to discuss the key messages from JPM24 and how these messages may impact the outlook of global biotech industry in 2024.

Speakers:

Tong Zhang, Ph.D.

CBO/CFO & Co-Founder

VelaVigo

Jing Yang, Ph.D.

CSO & Co-Founder

BaseCure Therapeutics

Lee Qian, CFA

Investment Manager

Baillie Gifford

Moderator:

Leon ‘Jun’ Tang, Ph.D., M.S.

Founder of InScienceWeTrust

Community

Organizers:

Partners & Collaborators:

| /

★

Registration

Date and Time:

Thur, Jan 11, 8:00 PM to 9:00 PM (EST)

Friday, Jan 12, 9:00 AM to 10:00 AM (BJT)

Speakers’ Bio

Tong Zhang, Ph.D.CBO/CFO &

Co-Founder

VelaVigo

上下滑动查看完整介绍

Dr. Tong Zhang is the co-founder, CBO/CFO of VelaVigo. Prior to VelaVigo he was Chief Business Officer at Shanghai Genechem, Managing Director at C-Bridge Capital (CBC), a healthcare focused PE, responsible for sourcing, evaluation and execution of investment opportunities focusing on China market, as well as incubating and managing portfolio companies.Prior to CBC Tong was head of Corporate BD at WuXi AppTec, responsible for strategic partnership and M&A, head of Business Development for MSD China and pan-regional BD lead for at Merck & Co., head of Business Development at EKR Therapeutics, a VC-backed specialty pharmaceutical company in the US. Tong also had investment experience as a Director at ESP Equity Partners, and equity analyst covering the US pharmaceutical industry for Credit Suisse in New York. Tong worked as a consultant for ISO HealthCare Consulting (now part of the Monitor Group) and Defined Health, leading strategy consulting firms in the biopharmaceutical industry.

Tong received his Ph.D. in Biology from Columbia University and a B.S. degree in Biology from Wuhan University in China. He also performed post-doctoral research at Sloan-Kettering Cancer Center in New York in the lab of Nobel Laureate Dr. James Rothman.

Jing Yang, Ph.D.CSO & Co-Founder

BaseCure

Therapeutics

上下滑动查看完整介绍

Jing currently serves as the Chief Scientific Officer, Co-founder and Board Director of BaseCure Therapeutics, a siRNA therapeutic startup company with proprietary platform technology and a rapidly growing pipeline. Jing is an accomplished drug hunter with over 20 years of experience leading multidisciplinary discovery research teams. In her previous roles at Johnson & Johnson and Bristol-Myers Squibb, Jing led the progression of numerous innovative drugs through the pipeline and successfully delivered three IND candidates for clinical research. Her expertise spans from small molecules, biologics, stem cells to RNAi research. Jing also held a number of leadership roles in Corporate and Non-Profit Organizations, most notably the Global Lead of Pan Asian Network at Bristol-Myers Squibb in 2019-2021 and President of Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP) in 2019-2020. Jing received her BS degree in Physical Chemistry at Sichuan University in China and her Ph.D degree in Glycobiology at Albert Einstein College of Medicine in New York. After completing her postdoctoral trainings at New England Medical Center and University of Pennsylvania, Jing held an Instructor position at the Center for Experimental Therapeutics and Department of Pharmacology at University of Pennsylvania. Jing is an author of 40 peer reviewed manuscripts and inventor of 14 patent applications.

Lee Qian, CFAInvestment Manager

Baillie Gifford

上下滑动查看完整介绍

Lee Qian is an investment manager at Baillie Gifford’s Positive Change Strategy. He joined Baillie Gifford in 2012 and is a CFA Charterholder. Lee graduated BA (Hons) in Economics and Management from the University of Oxford in 2012. Lee has a keen interest in sustainable development, across a range of topics including health, climate, and education. All views expressed will be his own.